Thu. 9 May 2024, 4:57pm ET
Benzinga
Earnings, Earnings Misses, News
INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.54) by 12.96 percent. This is a 69.44 percent decrease over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $14.000 thousand which missed the analyst consensus estimate of $30.000 thousand by 53.33 percent. This is a 63.16 percent decrease over sales of $38.000 thousand the same period last year.